Survey on RDN Procedure Volumes Fuels Optimism for Medtronic (MDT)

Group 1: Company Overview - Medtronic plc (NYSE:MDT) is a healthcare technology company that develops and sells medical devices and therapies, addressing over 70 chronic diseases and serving healthcare networks, clinicians, and patients directly [4] Group 2: Market Sentiment and Analyst Ratings - As of January 28, sentiment for Medtronic plc was moderately bullish, with 19 analysts covering the stock, resulting in 10 Buy ratings and 9 Hold ratings [1] - The median 1-year price target for Medtronic is $111.63, indicating an upside potential of almost 11% from the current level [1] Group 3: Analyst Forecasts and Concerns - Piper Sandler maintained a Neutral rating for Medtronic with a price target of $105, following a survey of 25 physicians regarding renal denervation (RDN) procedure volumes [2] - Survey results showed that expected volumes per physician for 2026 are below Piper Sandler's expectations, leading to a cautious forecast regarding RDN-linked growth potential, which is expected to contribute only an incremental 30 basis points to the topline [3]